Differentiating KIT null ES cells exhibit elevated levels of DNA laddering and reduced BCL2 expression, indicative of apoptosis. We conclude that mouse ES cell differentiation in vitro is dependent on the SCF-KIT pathway contrasting with the apparently normal differentiation of KIT null inner cell mass or epiblast cells in vivo. This discrepancy could be explained by the presence of compensatory signals in the embryo or it could lend support to the idea of a phenotypic relationship between ES cells and early germ cells. 
Introduction
The stem cell factor (SCF) receptor KIT is a member of family III of receptor tyrosine kinases (RTK) that activates a number of signalling pathways leading to a multitude of biological responses (Ashman, 1999) . Mutations in the genes encoding either KIT or SCF in mice result in pigmentation defects, anaemia and reduced fertility (Ashman, 1999) and loss-and gain-of-function mutations in KIT have been associated with human diseases including piebaldism and cancer (Kitamura and Hirotab, 2004; Pullarkat et al., 2000; Spritz, 1994) . The SCF-KIT pathway has been reported to be an important survival factor for many progenitor cell types including primordial germ cells (PGCs) (Dolci et al., 1991; Guerif et al., 2002; Mauduit et al., 1999; Yan et al., 2000) , haematopoietic stem cells (HSCs) (Caceres-Cortes et al., 1999; Engstrom et al., 2003; Galli et al., 1995; Keller et al., 1995; Young et al., 2006) , neuronal stem cells (Erlandsson et al., 2004) and melanocyte precursors (Ito et al., 1999; Wehrle-Haller and Weston, 1995) and it has been proposed that the SCF-KIT pathway promotes survival of these cell types by suppressing apoptosis. A correlation between Kit expression and pluripotency of embryonic stem (ES) cells has been reported (Palmqvist et al., 2005) which indirectly suggests that this signalling pathway may be important in a system with immense therapeutic potential (Keller, 2005) . We therefore aimed to determine directly whether the SCF-KIT pathway played a role in the survival or differentiation of murine ES cells.
Differentiating mouse ES cells express varying levels of SCF and KIT so it was difficult to control the activation of this signalling pathway using standard methods of cell starvation followed by addition of the ligand. We therefore developed a novel strategy to specifically activate a form of KIT in ES cells that is independent of the endogenous receptor and ligand. A gene-targeting strategy was used to knock out the Kit gene in ES cells and to knock in an SCF-independent form of the KIT receptor. We used a pharmacologically activatable form of KIT (FKB-KIT) where two FK506-binding domains (FKBP12) are fused to KIT-signalling domains . The FKB12 domains allow intracellular protein dimerisation and reversible activation in response to a lipid soluble dimeric form of the drug FK506, called AP20187. Using this system, we reveal that the SCF-KIT pathway plays a crucial role in the survival of differentiating ES cells in vitro by suppressing apoptosis through the pro survival protein, BCL2.
Results

Generation of mutant Kit ES cell lines
To produce a null allele at the Kit locus, E14 ES cells were electroporated with the targeting vector pGN⌬-kit (Fig. 1A) The stem cell factor (SCF)-KIT signal transduction pathway plays a role in the proliferation, differentiation and survival of a range of stem and progenitor cell types but little is known about its function in embryonic stem (ES) cells. We generated ES cells carrying a null allele of Kit as well as a knock-in allele that encodes an SCFindependent hybrid KIT receptor that can be activated by the FKBP binding drug, AP20187. KIT null ES cells die when induced to differentiate upon withdrawal of leukaemia inhibitory factor in monolayer culture. This phenotype is recapitulated in wild-type ES cells treated with a KIT-neutralising antibody and reversed in mutant cells by activation of the hybrid KIT receptor. (Bernex et al., 1996) . The targeting event resulted in the Kit W-lacZ allele in which the endogenous Kit gene is disrupted and the lacZ gene containing a nuclear localisation signal (NLS) and the neo gene are inserted in frame with the first six codons of Kit (Fig. 1B) . Two homologous recombinant clones were identified from 36 G418-resistant colonies using multiplex PCR (Fig. 1D ) and Southern blotting (Fig. 1E ). To generate homozygous Kit W-lacZ/W-lacZ ES cell lines, a heterozygous Kit W-lacZ/+ cell line was subjected to a high concentration of G418 (2 mg/ml) and seven highly G418-resistant null cell lines were established. Their genotype was confirmed by multiplex PCR (Fig. 1D ) and by Southern blotting (Fig. 1E) . To produce an allele encoding the KIT receptor with an FKB domain fused to the KIT intracellular domain the Kit W-lacZ/+ cell line was electroporated with the ⌬FKB-kit vector (Fig. 1C ). Colonies were selected in neomycin and hygromycin to identify ES cell clones in which both alleles of Kit had been targeted. Neomycin-and hygromycin-resistant cell lines were first screened by flow cytometry using an anti-KIT antibody (␣-CD117) (Fig. 1F ) and the genomic structure confirmed by Southern blotting (Fig.  1E) (15) colonies were stained for alkaline phosphatase activity (Jackson et al., 2004) (Fig. 2C) .
In 100 U/ml LIF there was no significant (P>0.05) difference in the number of stem cell colonies generated from Kit W-lacZ/W-lacZ and Kit W-lacZ/W-FKB cells when compared with Kit +/+ cells indicating that the lack of KIT signalling did not alter the self-renewal capacity of ES cells. However, there was a significant (P<0.05) difference in the number of colonies that were scored as mixed or differentiated generated from KIT null cells (Fig. 2D) , which suggests that the apparently reduced growth rate was due to the loss of spontaneously differentiating cells. These data provided the first hint that the KIT was involved in the production or survival of differentiating cells.
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W-lacZ/W-lacZ cell line isolated using high G418 concentrations from that line (data not shown).
Blocking the KIT pathway in wild-type ES cells results in a comparable phenotype Wild-type E14 ES cells were assayed for their self-renewal capacity in the presence of a monoclonal anti-Kit antibody, ACK2, an antagonistic blocker of KIT function . There was a slight (but not significant P>0.05) reduction in the total number of colonies generated in high concentrations of LIF in the presence of the antibody (Fig. 2E) . However in the absence of LIF, no colonies were generated in the presence of the antibody and at limiting concentrations of LIF a higher proportion of colonies had an undifferentiated phenotype compared to control cells (Fig. 2E ).
Differentiating KIT null cells die by apoptosis
We assessed whether the loss of colonies derived from Kit W-lacZ/W-lacZ and Kit W-lacZ/W-FKB ES cells on LIF withdrawal was due to programmed cell death. There was no significant (P>0.05) difference between the cell lines in the proportion of cells in G0-G1 and G2 phase of the cell cycle immediately after LIF withdrawal indicating that disruption of KIT signalling does not induce inappropriate cell-cycle arrest (Fig. 3A) . There was, however, a significant (P<0.05) difference in the pre-G1 peak between the Kit +/+ (30%) (Fig. 3B ). This further supports our hypothesis that in the absence of KIT signalling, differentiating ES cells die by apoptosis. It is interesting to note that a fragmentation ladder was detected in DNA from wild-type cells after LIF withdrawal when ten times as much DNA had been analysed (Duval et al., 2004) indicating that there is a quantitative rather than a qualitative difference between wild-type and KIT null cells. (Fig. 3C) . We tried to exclude the possibility that this staining represented an autofluorescent artefact of the null cells by comparing autoflourescent profiles of unstained cells (data not shown) and by minimising differences in staining or holding times between cell lines.
Furthermore we performed a number of control experiments including the depletion of apoptotic cells using an AnnexinV microbead kit (Miltenyi Biotec) The SCF-KIT signalling pathway promotes the survival of a number of progenitor cell types by upregulation of the pro-survival protein BCL2 (Carson et al., 1994; Dhandapani et al., 2005; Kimura et al., 2005; Zeuner et al., 2003) . This mechanism has also been implicated in the prevention of apoptosis in differentiating ES cells upon LIF withdrawal so we tested the expression of BCL2 in wild-type and KIT null cells (Fig. 3D) . BCL2 protein was detected at comparable levels in wild-type and KIT null cells grown in the presence of LIF and in wild-type cells after LIF withdrawal. However, no BCL2 was detected in KIT null cells growing in the absence of LIF which supports the hypothesis that KIT promotes the survival of differentiating ES cells and this is mediated at least in part via the BCL2 pathway.
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W-lacZ/W-FKB mutant phenotype is rescued upon pharmacological activation When maintained for two passages in LIF and in the presence of AP20187 Kit W-lacZ/W-FKB cells reverted to the more flattened morphology (data not shown) and growth rate (Fig. 4A) blotting using an antibody specific to the KIT phosphotyrosine 730 (pY730) (Fig. 4D) of AP20187 thus proving the specificity of KIT activation. These data strongly suggest that addition of AP20187 causes dimerisation of the FKB fusion protein leading to phosphorylation of the KIT intracellular domain and induction of downstream signalling in the SCF-KIT pathway.
Discussion
We have developed an inducible system that allows the activation of the SCF-KIT signalling pathway in ES cells in an environment devoid of complicating endogenous signalling and promiscuous ligands. We knocked out the endogenous Kit gene and subsequently knocked in the FKB-Kit fusion cDNA to the Kit locus by homologous recombination in ES cells. We report that differentiating ES cells devoid of KIT signalling die by apoptosis. This phenotype was partially recapitulated in wild-type ES cells using a blocking antibody and reversed when cells expressing FKB-Kit were grown in the presence of the dimerising agent, AP20187. It has been reported that up to 30% of wild-type cells undergo apoptosis when induced to differentiate on withdrawal of LIF (Duval et al., 2000) and we show that this increases to over 80% in cells devoid of KIT.
Interestingly we observed that a significant proportion of colonies were scored as 'undifferentiated' in limiting concentrations of LIF in self-renewal assays whereas wild-type cells produced only mixed or differentiated colonies under these conditions. This is possibly explained by the fact that 'mixed' colonies produced by Kit W-lacZ/W-lacZ and Kit W-lacZ/W-FKB cells might be scored as 'stem cell' colonies owing to the death of differentiated cells associated with these mixed colonies. It may also reflect a phenomenon comparable with that described in stem cell selection strategies whereby the continuous removal of differentiated cells by drug selection enhanced the derivation of pluripotent stem cells (McWhir et al., 1996) . It has been proposed that LIF-deprived ES cells undergo apoptotic crisis preceding differentiation because the apoptotic signals are a prerequisite for triggering ES cell differentiation (Duval et al., 2000) . Several pathways are induced in response to various apoptotic stimuli (Beere, 2005; Cho and Choi, 2002; Kim, 2002; Lavrik et al., 2005; Strasser et al., 2000) including the pro-and anti-apoptotic genes from the BCL2-BAX family (Green and Kroemer, 2005) . SCF-KIT has been reported to upregulate the expression of BCL2, a prosurvival protein, thereby preventing apoptosis in a number of cell types (Carson et al., 1994; Dhandapani et al., 2005; Jin et al., 2005; Kimura et al., 2005; Zeuner et al., 2003) and overexpression of BCL-2 prevents LIF-withdrawal-induced cell death of differentiating ES cells (Duval et al., 2004 ). We observed a high level of expression of BCL2 in both undifferentiated and differentiating wild-type ES cells and in undifferentiated KIT null ES cells but no BCL2 expression was detected in KIT null cells 4 days after LIF withdrawal. BCL2 expression is maintained and regulated by a number of different factors and mechanisms (Fan et al., 2005; Shore and Viallet, 2005 ) depending on the cell type and apoptotic signal. (Domen and Weissman, 2000; Kimura et al., 2005) . Our data indicate that BCL2 expression becomes KIT dependent upon induction of differentiation, whereas in the undifferentiated state it is controlled by other survival factors, probably including LIF signalling.
The fact that there is no apparent pre-implantation defect in mice lacking either KIT or SCF function (Geissler et al., 1981) suggests that the SCF-KIT signalling pathway is not essential for the survival of the differentiation products of the inner cell mass (ICM) from which ES cells are derived. This apparent discrepancy could be explained by genetic redundancy and the well-documented promiscuity between different receptorligand systems (Dubreuil et al., 1991; Waskow et al., 2004; Yu et al., 1998 ). An alternative explanation for the difference in phenotype between the ICM cell in vivo and ES cells in vitro could be the fact that ES cells do not accurately reflect their in vivo counterpart (Chambers and Smith, 2004) and in fact more closely resemble primordial germ cells (PGCs) (Zwaka and Thomson, 2005) . This has been primarily based on the comparison of marker expression between ES cells, PGCs and ICM (Zwaka and Thomson, 2005) . Interestingly KIT is expressed in ES cells and PGCs, but not ICM (Horie et al., 1991) and has been shown to play a crucial role in the survival and differentiation of primordial germ cells (Dessypris, 1994; Godin et al., 1991; Kissel et al., 2000; Matsui, 1998) . The phenotypic analysis of mice carrying a specific point mutation in Kit suggested that a block in KIT signalling could be compensated for by other pathways in hematopoiesis, melanogenesis and PGC development but not during the PGC differentiation processes of spermatogenesis and oogenesis (Kissel et al., 2000) . The fact that KIT null ES cells can survive and self renew but show an absolute requirement for KIT signalling for their survival during differentiation therefore provides another biological similarity between the ES cells and the germ cell lineage.
In conclusion, we have, for the first time, successfully used the pharmacologically inducible system to demonstrate a role for the SCF-KIT signal transduction pathway in ES cell survival during monolayer differentiation in vitro. As AP20187 can rescue the monolayer ES cells in vitro from death during the initial stages of differentiation we can now use this system to assess the role of SCF-KIT at later stages of differentiation into therapeutic cell populations. Furthermore proteomic approaches will provide a powerful strategy to define in detail the SCF-KIT signalling pathway in ES cells (Unwin et al., 2005) . As human ES cells are being considered as a source of mature cell types that could be used in regenerative medicine a more detailed understanding of the signalling pathways involved in ES cell survival and differentiation will aid in the development of protocols to produce optimal quantities of therapeutic cell types (Keller, 2005) .
Materials and Methods
Construction of the ⌬FKB-Kit targeting vector
To generate the ⌬FKB-Kit plasmid targeting vector, a 1200 base pair (bp) 5Ј arm of homology comparable to that used in the pGN⌬-kit targeting vector (Bernex et al., 1996) was PCR amplified from DNA isolated from the E14 ES cell genomic DNA, using the primer pair OJB1-TGATACACAAGCATCCGTAACTCTA and OJB2-GGGTGCAGTCCTCTTGTCTG. The resulting amplicon was cloned into the pCR4-TOPO vector (Invitrogen), and an EcoR1 fragment from that was subsequently cloned into the multiple cloning site (MCS) of Vitality-phrGFP2a vector (Stratagene). The unnecessary IRES-hrGFP fragment was removed from this vector by XhoI-PstI digestion and a 4122bp XhoI-PstI fragment from pBJF3KIT, corresponding to the FKB-Kit chimaeric cDNA , was cloned inframe with the 1200 bp 5Ј arm of homology to generate pKPF3K3. After removing the 667 bp CMV promoter from pKPF3K3 by NsiI-NotI digestion, a 6100bp NsiINotI fragment from pGN⌬-kit was cloned into pKPF3K3, to generate pKPF3K3.1. The Vitality-phrGFP2a vector allows for directional insertion of eukaryotic resistance genes, contained in prefabricated modules, into the core vector, by Cremediated recombination. A 3100 bp pExchange module EC-Hyg (Stratagene) was introduced into pKPF3K3.1 by Cre mediated site-specific recombination to introduce a floxed hygromycin resistance cassette into the final ⌬FKB-kit targeting vector that was linearised at the unique SrfI site before electroporation.
ES cell maintenance
The feeder-independent mouse E14 parental ES cell line was maintained in Glasgow's minimal essential medium (GMEM) as described (Jackson et al., 2002) without feeders and in the presence of leukaemia inhibitory factor (LIF). LIF was produced as described previously and involved the collection of conditioned medium from COS7 cells transfected with the pDR10 LIF-DIA expression construct (a gift from Austin Smith) (Smith, 1991) . LIF-containing supernatant was tested and the concentration that showed detectable inhibition of ES cell differentiation was defined as 10 U/ml then 100 U/ml was used in standard maintenance medium. W-lacZ/+ cells were electoporated with the SrfI-linearised ⌬FKB-Kit vector and selected with 150 g/ml G418 and 175 g/ml hygromycin for 10 days. In all cases, resistant colonies were picked, replicated in 96-well dishes and genomic DNA was isolated from expanded colonies for screening, using established protocols (Laird et al., 1991) .
Electroporation of targeting vectors
Screening of homologous recombinants
Multiplex PCR was used to screen for correctly targeted Kit W-lacZ/+ and Kit W-lacZ/W-lacZ colonies using primer set: OJB56, AGTTGGCGCATGACTTTAAT; OJB57, AAAGCCAACAGCTACCACTC; OJB58, ACAGATGAAACGCCGAG-TTA; and the Amplitaq gold enzyme (Applied Biosystems). Potential Kit W-lacZ/W-FKB clones were screened by flow cytometry using the tricolor conjugate KIT-specific antibody (␣-CD117) (Caltag Medsystems) then confirmed by Southern blotting (Bashamboo et al., 2005) of EcoRI-digested genomic DNA, hybridised using an external probe (Bernex et al., 1996) .
Self-renewal assays
ES cells were plated in duplicate onto 35-mm gelatin-coated wells at a density of 1ϫ10 3 cells per well in ES cell medium containing 100, 10, 1 or 0 U/ml LIF. After 5 days, colonies were stained for alkaline phosphatase activity using the AP leukocyte kit (Sigma, Poole, Dorset, UK) then examined microscopically for morphology and intensity of staining and scored as either 'stem cell', 'mixed' or 'differentiated' (Jackson et al., 2004) . Statistical analysis was carried out by MannWhitney U test using the GraphPad Prism software (GraphPad Software), P<0.05 was considered statistically significant.
Blocking KIT activity using ACK2 E14 ES cells were cultured for 2 days in ES cell medium with LIF and 10 ng/ml ACK2 (Insight Biotechnology) then plated in self-renewal assays as above in the presence or absence of ACK2.
Pharmacological activation using AP20187
AP20187, a synthetic dimer that can be used to induce dimerisation of mutant FKBP12 domains was a gift from ARIAD Pharmaceuticals (Cambridge, MA; www.ariad.com/regulationkits). ES cell survival and self-renewal assays determined the optimal dose of 10 nM (data not shown). To activate the FKB-KIT fusion protein, ES cells were cultured in ES cell medium with 100 U/ml LIF and 10 nM AP20187 for two passages then plated in the standard self-renewal assays with or without AP20187.
Western blotting
Western blotting was performed as previously described using the anti-KIT phospho-antibody (pY730) (Biosource), anti-GAPDH monoclonal antibody
